MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1

Yao,Jian; Zhang,Ping; Li,Jin; Xu,Wei

doi:10.3892/ol.2017.6200

MicroRNA-215 acts as a tumor suppressor in breast cancer by targeting AKT serine/threonine kinase 1

Authors:
- Jian Yao
- Ping Zhang
- Jin Li
- Wei Xu
View Affiliations

Affiliations: Department of Integrated Traditional Chinese and Western Medicine, First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China
Published online on: May 17, 2017 https://doi.org/10.3892/ol.2017.6200
Pages: 1097-1104

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There are accumulating reports that microRNAs are dysregulated in a number of human cancer types, and that they may function as tumor suppressors or oncogenes in tumorigenesis and tumor development. microRNA‑215 (miR‑215) has been identified as a tumor suppressor in epithelial ovarian, pancreatic, non‑small cell lung and colon cancer, whereas it may act as an oncogene in gastric and cervical cancer. The role of miR‑215 in breast cancer carcinogenesis and progression has yet to be elucidated. In the present study, the expression level of miR‑215 was determined in breast cancer tissues and cell lines using the reverse transcription‑quantitative polymerase chain reaction. The effects of miR-215 overexpression on proliferation and the invasive capacity of breast cancer cells were assessed using MTT and cell invasion assays. The results revealed that miR‑215 was significantly downregulated in breast cancer tissues and cell lines. Restoration of miR‑215 expression inhibited the proliferation and invasion of breast cancer cells. The underlying molecular mechanism for the suppression of proliferation and invasion by miR‑215 was investigated. AKT serine/threonine kinase 1 (AKT1) was validated as a novel direct target of miR‑215, and the effect of AKT1 small interfering RNA mimicked the effect of miR‑215 overexpression in breast cancer cells. These results indicated that miR‑215 acted as a tumor suppressor, and that its downregulation in tumor tissues may contribute to the carcinogenesis and progression of breast cancer, indicating that miR‑215 may be a novel therapeutic target for the treatment of breast cancer.

View Figures

View References

1	Singh R, Yadav V, Kumar S and Saini N: MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN HMGCR, ACACA and CYP27B1. Sci Rep. 5:174542015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Eroles P, Tormo E, Pineda B, Espin E and Lluch A: MicroRNAs in breast cancer: One more turn in regulation. Curr Drug Targets. 17:1083–1100. 2016. View Article : Google Scholar : PubMed/NCBI
4	Nakamura S, Yagata H, Ohno S, Yamaguchi H, Iwata H, Tsunoda N, Ito Y, Tokudome N, Toi M, Kuroi K and Suzuki E: Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer. 17:199–204. 2010. View Article : Google Scholar : PubMed/NCBI
5	Gong Y, He T, Yang L, Yang G, Chen Y and Zhang X: The role of miR-100 in regulating apoptosis of breast cancer cells. Sci Rep. 5:116502015. View Article : Google Scholar : PubMed/NCBI
6	Muenst S, Däster S, Obermann EC, Droeser RA, Weber WP, von Holzen U, Gao F, Viehl C, Oertli D and Soysal SD: Nuclear expression of snail is an independent negative prognostic factor in human breast cancer. Dis Markers. 35:337–344. 2013. View Article : Google Scholar : PubMed/NCBI
7	Lu L, Ju F, Zhao H and Ma X: MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating ABCC1. Biotechnol Lett. 37:2387–2394. 2015. View Article : Google Scholar : PubMed/NCBI
8	Zielinska HA, Bahl A, Holly JM and Perks CM: Epithelial-to-mesenchymal transition in breast cancer: A role for insulin-like growth factor I and insulin-like growth factor-binding protein 3? Breast Cancer (Dove Med Press). 7:9–19. 2015.PubMed/NCBI
9	Pdel C Monroig, Chen L, Zhang S and Calin GA: Small molecule compounds targeting miRNAs for cancer therapy. Adv Drug Deliv Rev. 81:104–116. 2015. View Article : Google Scholar : PubMed/NCBI
10	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
11	Smith L, Baxter EW, Chambers PA, Green CA, Hanby AM, Hughes TA, Nash CE, Millican-Slater RA, Stead LF, Verghese ET and Speirs V: Down-regulation of miR-92 in breast epithelial cells and in normal but not tumour fibroblasts contributes to breast carcinogenesis. PLoS One. 10:e01396982015. View Article : Google Scholar : PubMed/NCBI
12	Fei B and Wu H: MiR-378 inhibits progression of human gastric cancer MGC-803 cells by targeting MAPK1 in vitro. Oncol Res. 20:557–564. 2012. View Article : Google Scholar : PubMed/NCBI
13	Wang Z, Yin B, Wang B, Ma Z, Liu W and Lv G: MicroRNA-210 promotes proliferation and invasion of peripheral nerve sheath tumor cells targeting EFNA3. Oncol Res. 21:145–154. 2013. View Article : Google Scholar : PubMed/NCBI
14	Misawa A, Katayama R, Koike S, Tomida A, Watanabe T and Fujita N: AP-1-Dependent miR-21 expression contributes to chemoresistance in cancer stem cell-like SP cells. Oncol Res. 19:23–33. 2010. View Article : Google Scholar : PubMed/NCBI
15	Ohdaira H, Sekiguchi M, Miyata K and Yoshida K: MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif. 45:32–38. 2012. View Article : Google Scholar : PubMed/NCBI
16	Cao Q, Liu F, Ji K, Liu N, He Y, Zhang W and Wang L: MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression. J Exp Clin Cancer Res. 36:292017. View Article : Google Scholar : PubMed/NCBI
17	Tomasetti M, Santarelli L, Neuzil J and Dong L: MicroRNA regulation of cancer metabolism: Role in tumour suppression. Mitochondrion. 19:29–38. 2014. View Article : Google Scholar : PubMed/NCBI
18	Rusek AM, Abba M, Eljaszewicz A, Moniuszko M, Niklinski J and Allgayer H: MicroRNA modulators of epigenetic regulation, the tumor microenvironment and the immune system in lung cancer. Mol Cancer. 14:342015. View Article : Google Scholar : PubMed/NCBI
19	Hurst DR, Edmonds MD and Welch DR: Metastamir: The field of metastasis-regulatory microRNA is spreading. Cancer Res. 69:7495–7498. 2009. View Article : Google Scholar : PubMed/NCBI
20	Tang H, Liu P, Yang L and Xie X, Ye F, Wu M, Liu X, Chen B, Zhang L and Xie X: miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer. Mol Cancer Ther. 13:3185–3197. 2014. View Article : Google Scholar : PubMed/NCBI
21	Pu Q, Huang Y, Lu Y, Peng Y, Zhang J, Feng G, Wang C, Liu L and Dai Y: Tissue-specific and plasma microRNA profiles could be promising biomarkers of histological classification and TNM stage in non-small cell lung cancer. Thorac Cancer. 7:348–354. 2016. View Article : Google Scholar : PubMed/NCBI
22	Song J, Bai Z, Zhang J, Meng H, Cai J, Deng W, Bi J, Ma X and Zhang Z: Serum microRNA-21 levels are related to tumor size in gastric cancer patients but cannot predict prognosis. Oncol Lett. 6:1733–1737. 2013.PubMed/NCBI
23	Bartels CL and Tsongalis GJ: MicroRNAs: Novel biomarkers for human cancer. Ann Biol Clin (Paris). 68:263–272. 2010.PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Ju X, Katiyar S, Wang C, Liu M, Jiao X, Li S, Zhou J, Turner J, Lisanti MP, Russell RG, et al: Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci USA. 104:pp. 7438–7443. 2007; View Article : Google Scholar : PubMed/NCBI
26	Deng Y, Huang Z, Xu Y, Jin J, Zhuo W, Zhang C, Zhang X, Shen M, Yan X, Wang L, et al: MiR-215 modulates gastric cancer cell proliferation by targeting RB1. Cancer Lett. 342:27–35. 2014. View Article : Google Scholar : PubMed/NCBI
27	Xu YJ and Fan Y: MiR-215/192 participates in gastric cancer progression. Clin Transl Oncol. 17:34–40. 2015. View Article : Google Scholar : PubMed/NCBI
28	Li N, Zhang QY, Zou JL, Li ZW, Tian TT, Dong B, Liu XJ, Ge S, Zhu Y, Gao J and Shen L: miR-215 promotes malignant progression of gastric cancer by targeting RUNX1. Oncotarget. 26:4817–4828. 2016.
29	Liang H, Li Y, Luo RY and Shen FJ: MicroRNA-215 is a potential prognostic marker for cervical cancer. J Huazhong Univ Sci Technolog Med Sci. 34:207–212. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ge G, Zhang W, Niu L, Yan Y, Ren Y and Zou Y: miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis. Oncol Rep. 35:1816–1822. 2016.PubMed/NCBI
31	Li QW, Zhou T, Wang F, Jiang M, Liu CB, Zhang KR, Zhou Q, Tian Z and Hu KW: MicroRNA-215 functions as a tumor suppressor and directly targets ZEB2 in human pancreatic cancer. Genet Mol Res. 14:16133–16145. 2015. View Article : Google Scholar : PubMed/NCBI
32	Hou Y, Zhen J, Xu X, Zhen K, Zhu B, Pan R and Zhao C: miR-215 functions as a tumor suppressor and directly targets ZEB2 in human non-small cell lung cancer. Oncol Lett. 10:1985–1992. 2015.PubMed/NCBI
33	Zhou SW, Su BB, Zhou Y, Feng YQ, Guo Y, Wang YX, Qi P and Xu S: Aberrant miR-215 expression is associated with clinical outcome in breast cancer patients. Med Oncol. 31:2592014. View Article : Google Scholar : PubMed/NCBI
34	Karaayvaz M, Pal T, Song B, Zhang C, Georgakopoulos P, Mehmood S, Burke S, Shroyer K and Ju J: Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer. 10:340–347. 2011. View Article : Google Scholar : PubMed/NCBI
35	Ge G, Zhang W, Niu L, Yan Y, Ren Y and Zou Y: miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis. Oncol Rep. 35:1816–1822. 2016.PubMed/NCBI
36	Yu Z, Ni L, Chen D, Zhang Q, Su Z, Wang Y, Yu W, Wu X, Ye J, Yang S, et al: Identification of miR-7 as an oncogene in renal cell carcinoma. J Mol Histol. 44:669–677. 2013. View Article : Google Scholar : PubMed/NCBI
37	Agarwal E, Brattain MG and Chowdhury S: Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
38	Kang B, Hao C, Wang H, Zhang J, Xing R, Shao J, Li W, Xu N, Lu Y and Liu S: Evaluation of hepatic-metastasis risk of colorectal cancer upon the protein signature of PI3K/AKT pathway. J Proteome Res. 7:3507–3515. 2008. View Article : Google Scholar : PubMed/NCBI
39	Altomare DA and Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464. 2005. View Article : Google Scholar : PubMed/NCBI
40	Zhang G, Liu Z, Xu H and Yang Q: miR-409-3p suppresses breast cancer cell growth and invasion by targeting Akt1. Biochem Biophys Res Commun. 469:189–195. 2016. View Article : Google Scholar : PubMed/NCBI
41	Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV and Cheng JQ: AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 159:431–437. 2001. View Article : Google Scholar : PubMed/NCBI